Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Inclusion Criteria:

- Is HIV-1 positive and has HIV treatment indicated based on physician assessment.

- Has received no (0 days of) antiretroviral therapy (ART), including investigational
antiretroviral agents.

- Is considered clinically stable with no signs or symptoms of active infection for at
least 2 weeks prior to the start of treatment.

- Female is highly unlikely to become pregnant, or male is highly unlikely to
impregnate a partner because they are not of reproductive potential, or agree to
practice abstinence or use acceptable contraception for up to 14 days after the last
dose of study drug.

Exclusion Criteria:

- Uses or has had a recent history of using recreational or illicit drugs.

- Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
agent that is active against HIV-1.

- Has documented or known resistance to study drugs including MK-1439, darunavir,
ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.

- Has participated in a study with an investigational compound/device within the prior
month, or anticipates doing so during this study.

- Has used systemic immunosuppressive therapy or immune modulators within the prior 30
days, or anticipates doing so during this study.

- Has significant hypersensitivity or other contraindication to any of the components
of the study drugs.

- Has a current (active) diagnosis of acute hepatitis due to any cause.

- Is pregnant, breastfeeding or expecting to conceive at any time during the study.

- Female who expects to donate eggs, or male who expects to donate sperm at any time
during the study.